U.S. Stem Cell Revenue and Competitors

Miami, FL USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • U.S. Stem Cell's estimated annual revenue is currently $2.5M per year.(i)
  • U.S. Stem Cell's estimated revenue per employee is $155,000

Employee Data

  • U.S. Stem Cell has 16 Employees.(i)
  • U.S. Stem Cell grew their employee count by -6% last year.

U.S. Stem Cell's People

NameTitleEmail/Phone
1
Chief Science OfficerReveal Email/Phone
2
CFOReveal Email/Phone
3
VP Sales and MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.3M995%N/AN/A
#2
$1.1M7-30%N/AN/A
#3
$3.7M244%N/AN/A
#4
$4.3M28-3%N/AN/A
#5
$2.5M16N/AN/AN/A
#6
$0.8M50%N/AN/A
#7
$1.1M70%N/AN/A
#8
$2.5M167%N/AN/A
#9
$1.4M9-25%N/AN/A
#10
$0.6M40%N/AN/A
Add Company

What Is U.S. Stem Cell?

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$2.5M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M16-24%N/A
#2
$3M1713%N/A
#3
N/A17-19%N/A
#4
$2.8M186%N/A
#5
$1.7M1919%N/A